image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - IE
$ 6.69
-1.62 %
$ 646 M
Market Cap
-13.12
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one AVDL stock under the worst case scenario is HIDDEN Compared to the current market price of 6.69 USD, Avadel Pharmaceuticals plc is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one AVDL stock under the base case scenario is HIDDEN Compared to the current market price of 6.69 USD, Avadel Pharmaceuticals plc is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one AVDL stock under the best case scenario is HIDDEN Compared to the current market price of 6.69 USD, Avadel Pharmaceuticals plc is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart AVDL

image
$17.0$17.0$16.0$16.0$15.0$15.0$14.0$14.0$13.0$13.0$12.0$12.0$11.0$11.0$10.0$10.0$9.0$9.0$8.0$8.0$7.0$7.0$6.0$6.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
169 M REVENUE
504.79%
-42.4 M OPERATING INCOME
69.24%
-48.8 M NET INCOME
69.53%
-46.9 M OPERATING CASH FLOW
63.50%
51.8 M INVESTING CASH FLOW
203.37%
16 M FINANCING CASH FLOW
-88.20%
50.4 M REVENUE
0.77%
-3.3 M OPERATING INCOME
-908.26%
-5.04 M NET INCOME
-92.11%
7.87 M OPERATING CASH FLOW
214.27%
14.9 M INVESTING CASH FLOW
194.86%
880 K FINANCING CASH FLOW
-25.23%
Balance Sheet Avadel Pharmaceuticals plc
image
Current Assets 134 M
Cash & Short-Term Investments 73.8 M
Receivables 34.1 M
Other Current Assets 26.3 M
Non-Current Assets 30 M
Long-Term Investments 0
PP&E 2.16 M
Other Non-Current Assets 27.9 M
44.92 %20.76 %16.03 %16.97 %Total Assets$164.2m
Current Liabilities 48.8 M
Accounts Payable 7.33 M
Short-Term Debt 582 K
Other Current Liabilities 40.9 M
Non-Current Liabilities 41.6 M
Long-Term Debt 1.12 M
Other Non-Current Liabilities 40.4 M
8.11 %45.28 %44.73 %Total Liabilities$90.4m
EFFICIENCY
Earnings Waterfall Avadel Pharmaceuticals plc
image
Revenue 169 M
Cost Of Revenue 15.3 M
Gross Profit 154 M
Operating Expenses 196 M
Operating Income -42.4 M
Other Expenses 6.43 M
Net Income -48.8 M
200m200m150m150m100m100m50m50m00(50m)(50m)169m(15m)154m(196m)(42m)(6m)(49m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
90.97% GROSS MARGIN
90.97%
-25.07% OPERATING MARGIN
-25.07%
-28.87% NET MARGIN
-28.87%
-66.13% ROE
-66.13%
-29.73% ROA
-29.73%
-36.37% ROIC
-36.37%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Avadel Pharmaceuticals plc
image
100m100m50m50m00(50m)(50m)(100m)(100m)(150m)(150m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -48.8 M
Depreciation & Amortization 2.68 M
Capital Expenditures 0
Stock-Based Compensation 20.4 M
Change in Working Capital -20.3 M
Others 14.2 M
Free Cash Flow -46.9 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Avadel Pharmaceuticals plc
image
Wall Street analysts predict an average 1-year price target for AVDL of $24.2 , with forecasts ranging from a low of $19 to a high of $30 .
AVDL Lowest Price Target Wall Street Target
19 USD 184.01%
AVDL Average Price Target Wall Street Target
24.2 USD 262.48%
AVDL Highest Price Target Wall Street Target
30 USD 348.43%
Price
Max Price Target
Min Price Target
Average Price Target
3030252520201515101055May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 12
6. Ownership
Insider Ownership Avadel Pharmaceuticals plc
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
39.6 K USD 1
0-3 MONTHS
722 K USD 6
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Avadel Pharmaceuticals to Present at the 24th Annual Needham Healthcare Conference DUBLIN, April 01, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the 24th Annual Needham Healthcare Conference on Tuesday, April 8 at 1:30 p.m. ET. globenewswire.com - 2 weeks ago
Avadel Announces Publications in CNS Drugs Supplement Highlighting Key Clinical Issues for People with Narcolepsy and Their Clinicians DUBLIN, March 25, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the publication of six manuscripts covering clinical management, shared decision-making and goal setting for people with narcolepsy and their clinicians in a CNS Drugs supplement titled “A New Dawn in the Management of Narcolepsy”. globenewswire.com - 3 weeks ago
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences DUBLIN, Ireland, March 05, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences: Leerink Global Biopharma Conference: Fireside chat on Wednesday, March 12 at 9:20 a.m. ET. UBS Virtual CNS Day: Fireside chat on Monday, March 17 at 8:30 a.m. globenewswire.com - 1 month ago
Avadel Pharmaceuticals plc (AVDL) Q4 2024 Earnings Call Transcript Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Q4 2024 Earnings Conference Call March 3, 2025 8:30 AM ET Company Participants Austin Murtagh - Precision AQ Gregory Divis - Chief Executive Officer Thomas McHugh - Chief Financial Officer Conference Call Participants François Brisebois - Oppenheimer Poorna Kannan - Needham & Company Oren Livnat - H.C. Wainwright & Co. David Amsellem - Piper Sandler & Co. Madhumita Yennawar - Leerink Partners Myriam Belghiti - LifeSci Capital David Hoang - Deutsche Bank AG Brandon Folkes - Rodman & Renshaw Research Operator Greetings, and welcome to Avadel Pharmaceuticals' Fourth Quarter and Business Update Conference Call. seekingalpha.com - 1 month ago
Avadel Pharmaceuticals Reiterates 2025 Guidance as it Reports Fourth Quarter and Full Year 2024 Financial Results -- LUMRYZ™ generated $50.4 million in sales in the fourth quarter, up 158% year-over-year, taking the full-year total to $169.1 million, in line with preliminary results published January 8 -- Reiterates 2025 guidance, with the number of patients on LUMRYZ expected to increase to 3,300-3,500 by year-end, generating $240-$260 million in net product revenue and cash flow of $20-40 million -- Executing multiple initiatives to accelerate patient demand for LUMRYZ -- Patient enrollment is on track in the Phase 3 REVITALYZ™ study to evaluate efficacy and safety of LUMRYZ in Idiopathic Hypersomnia (IH) -- Avadel management to host a conference call today at 8:30 a.m. ET DUBLIN, March 03, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced its financial results for the fourth quarter and full year ended December 31, 2024. globenewswire.com - 1 month ago
Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on March 3 DUBLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, March 3, 2025, to provide a corporate update and discuss the Company's financial results for the fourth quarter and full year ended December 31, 2024. globenewswire.com - 1 month ago
Avadel Pharmaceuticals Appoints Kevin Springman as Vice President of Sales DUBLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced that Kevin Springman has joined the company as Vice President of Sales. Mr. Springman is an accomplished executive with experience leading sales, market access and commercial teams, and executing rare disease drug launches in competitive markets. globenewswire.com - 1 month ago
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) DUBLIN, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel's Board of Directors approved the grant of non-statutory options to five (5) new employees to purchase 173,000 ordinary shares under Avadel's 2021 Inducement Plan. The awards were granted as an inducement material to the employee's acceptance of employment with Avadel in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and vest over four years, with 25% vesting on the one-year anniversary of each new employee's respective start date and 25% vesting on the second, third, and fourth anniversary thereafter. The options are subject to the terms and conditions of Avadel's 2021 Inducement Plan approved by the Board of Directors in November 2021 and the terms and conditions of award agreements covering the grants. globenewswire.com - 1 month ago
Avadel Pharmaceuticals: Moving To A Speculative Buy Avadel Pharmaceuticals' primary asset, LUMRYZ, treats narcolepsy and is in Phase 3 trials for Idiopathic Hypersomnia, with significant revenue growth potential. Recent news includes the resignation of the Chief Commercial Officer, strong Q4 revenue growth, and a push from ASL Strategic Value Fund for strategic alternatives. Analysts are universally positive, with multiple Buy ratings and price targets ranging from $12 to $22, despite some downward revisions. seekingalpha.com - 2 months ago
ASL Strategic Value Fund Letter to Avadel Pharmaceuticals (AVDL: NASDAQ) Board of Directors CHESTERFIELD, Mo.--(BUSINESS WIRE)--The following is a letter that ASL Strategic Value Fund sent to the Board of Directors of Avadel Pharmaceuticals (NASDAQ:AVDL): February 10, 2025 Mr. Geoff Glass Chairman, Board of Directors Avadel Pharmaceuticals Plc 16640 Chesterfield Grove Road, Suite 200 Chesterfield, Mo 63005 Dear Geoff: As you are aware, the ASL Strategic Value Fund has been a long-term investor in Avadel Pharmaceuticals. Our ownership predates most of the directors on the current Board. businesswire.com - 2 months ago
There May Still Be Time to Get in on These 3 Trending Biotechs Despite the strength of the economy overall, 2024 was a challenging year for the biotech industry. The high cost of borrowing—particularly prior to the Fed's first rate cut in several years in September—coupled with a shifting landscape for the healthcare sector dampened prospects for many firms. marketbeat.com - 2 months ago
3 Oversold Biotech Names High beta market sectors, including small caps and biotech, sold off significantly last week as the 10-Year Treasury yield surpassed 4.75%. The JP Morgan Healthcare event in San Francisco that opens today and runs through most of the week could boost sentiment on the biotech sector. In the paragraphs below, I highlight three biotech/biopharma names that appear oversold at current trading levels. seekingalpha.com - 3 months ago
8. Profile Summary

Avadel Pharmaceuticals plc AVDL

image
COUNTRY IE
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 646 M
Dividend Yield 0.00%
Description Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Contact 10 Earlsfort Terrace, Dublin, 2 https://www.avadel.com
IPO Date June 7, 1996
Employees 188
Officers Dr. Jordan S. Dubow M.D. Consultant Mr. Thomas S. McHugh Senior Vice President, Principal Financial & Accounting Officer and Chief Financial Officer Ms. Angie Woods Vice President of People & Culture Mr. Jerad G. Seurer General Counsel, Company Secretary & Compliance Officer Mr. Gregory J. Davis Vice President of Corporate and Business Development Mr. Gregory J. Divis Jr. Chief Executive Officer & Director Mr. Mark W. Elrod Vice President of Sales Dr. Jason M. Vaughn Senior Vice President of Technical Operations Ms. Jennifer Gudeman PharmD Senior Vice President of Medical & Clinical Affairs